Close

More on CEPH

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (0.6 Score)
- Holders

Financials

Income Statement
Balance Sheet
Cash Flow Statement

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

CEPH Cash Flow Statement

Click line-items for a historical chart and %
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income 326.8M
Adjustments to reconcile net income to net cash provided by operating activities:
Deferred income tax expense (benefit) 52.16M
Shortfall tax benefits from stock-based compensation -331K
Depreciation and amortization 93.39M
Stock-based compensation expense 16.95M
Amortization of debt discount and debt issuance costs 32.78M
Changes in fair value of investments -264.21M
Loss (gain) on foreign exchange contracts -5.09M
Impairment and (gain) loss on sale of assets 54.06M
Other 23.09M
Changes in operating assets and liabilities, net of acquisitions:
Receivables -37.53M
Inventory 5.65M
Other assets 1.21M
Accounts payable and accrued expenses -11.45M
Other liabilities -65.46M
Net cash provided by operating activities 222.01M
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment -28.05M
Proceeds from sale of property and equipment 818K
Cash balance from consolidation of variable interest entity 15.51M
Acquisition of Mepha GmbH, net of cash acquired 0
Acquisition of GeminX Pharmaceuticals, Inc., net of cash acquired -184.2M
Acquisition of ChemGenex Ltd., net of cash acquired -179.93M
Purchases of investments -135.45M
(Cash settlements of) proceeds from foreign exchange contracts 7.11M
Net cash used for investing activities -504.19M
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock under the employee stock purchase plan 349K
Proceeds from exercises of common stock options 133.7M
Windfall tax benefits from stock-based compensation 12.06M
Acquisition of treasury stock 0
Payments on and retirements of long-term debt -35.76M
Acquisition of Ception Therapeutics, Inc. noncontrolling interest 0
Acquisition of ChemGenex Ltd. noncontrolling interest -6.6M
Net cash provided by (used for) financing activities 103.75M
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS 15.67M
NET DECREASE IN CASH AND CASH EQUIVALENTS -162.76M
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 1.16B
CASH AND CASH EQUIVALENTS, END OF PERIOD 997.48M

Entities mentioned with CEPH

View All Entities